THERAPEUTIC GOODS ADMINISTRATION TGA

Neurotech to commence clinical study program this quarter

Finfeed Archived Feb 15, 2021

Following the successful in vitro findings, Neurotech (ASX: NTI) has begun designing a phase I/II study to assess the safety and efficacy of the novel NTI/Dolce strain in a paediatric population.

Creso Pharma set to benefit from OTC cannabidiol sales in Australia

Finfeed Archived Feb 01, 2021

Creso Pharma (ASX: CPH) is prepared to meet demand as OTC sales of low-dose cannabidiol products start in Australian pharmacies.

How Creso Pharma could benefit from TGA down-scheduling of CBD

Finfeed Archived Dec 15, 2020

Creso Pharma (ASX: CPH) is positioned to significantly benefit from a TGA decision to down-schedule low dose CBD preparations.

Creso Pharma is a step closer to unlocking Australian market

Finfeed Archived Dec 11, 2020

Creso Pharma Limited (ASX:CPH, FRA:1X8) has today announced obtainment of an exclusive Heads of Agreement with leading natural, sustainable health and lifestyle brand supplier Martin & Pleasance Pty Ltd.

Creso up 50% in a week with further catalysts imminent

Finfeed Archived Dec 02, 2020

Creso Pharma (ASX: CPH) has received three new purchase orders totalling $414,000 for its anibidiol® line of animal health products.

Changes to OTC cannabis sales just around the corner

Finfeed Archived Nov 26, 2020

The Therapeutic Goods Administration (TGA) will shortly bring down its final decision regarding a major regulatory change in the distribution of cannabidiol (CBD) products in Australia, which could hellp stocks such as Creso Pharma (ASX: CPH).

Creso Pharma to benefit from OTC cannabis sales in Australia

Finfeed Archived Sep 10, 2020

The TGA has recommended that CBD products be down-scheduled to schedule 3 medicines in Australia, allowing OTC sales, which should benefit Creso Pharma (ASX: CPH).